
Cancer Genetics (Vyant Bio)
Cancer Genetics is laboratory that develops and commercializes proprietary genomic tests and services to empower cancer treatment.
Market cap
$1.2m
Enterprise value
($7m)
Share price
$0.26 VYNT
Recent deals
USD | 2020 | 2021 | 2022 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | 32 % | (42 %) |
EBITDA | 0000 | 0000 | 0000 |
% EBITDA margin | (584 %) | (651 %) | (2263 %) |
Profit | 0000 | 0000 | 0000 |
% profit margin | (998 %) | (3559 %) | (3407 %) |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
R&D % of revenue | 373 % | 372 % | 1017 % |
Source: Company filings or news article
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Cancer Genetics (Vyant Bio)
Edit
ACQUISITION by Cancer Genetics (Vyant Bio) Aug 2015

ACQUISITION by Cancer Genetics (Vyant Bio) Jul 2014

ACQUISITION by Cancer Genetics (Vyant Bio) Aug 2017